Nunzia Pharmaceutical Company
NUNZ
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1,031.34% | -99.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1,031.34% | -99.89% | |||
| Operating Income | -1,031.34% | 99.89% | |||
| Income Before Tax | -1,076.12% | 99.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,076.12% | 99.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,076.12% | 99.89% | |||
| EBIT | -1,031.34% | 99.89% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -- | 100.00% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | -- | 100.00% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | 0.06% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||